Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).

Žáčková,  Daniela; Faber,  Edgar; Stejskal, L.; Karas, M.; Bělohlávková, P.; Klamová, H.; Černá, O.; Cmunt,  Eduard; Čičátková,  Petra; Semerád,  Lukáš; Horňák,  Tomáš; Kvetková,  Anežka; Procházková,  Jiřina; Rychlíčková,  Jitka; Štěpánová,  Radka; Svobodník,  Adam; Machová Poláková,  Kateřina; Ježíšková,  Ivana; Jurček,  Tomáš; Borský,  Marek; Wiewiorka,  Ondřej; Mayer,  Jiří

Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ŽÁČKOVÁ Daniela FABER Edgar STEJSKAL L. KARAS M. BĚLOHLÁVKOVÁ P. KLAMOVÁ H. ČERNÁ O. CMUNT Eduard ČIČÁTKOVÁ Petra SEMERÁD Lukáš HORŇÁK Tomáš KVETKOVÁ Anežka PROCHÁZKOVÁ Jiřina RYCHLÍČKOVÁ Jitka ŠTĚPÁNOVÁ Radka SVOBODNÍK Adam MACHOVÁ POLÁKOVÁ Kateřina JEŽÍŠKOVÁ Ivana JURČEK Tomáš BORSKÝ Marek WIEWIORKA Ondřej MAYER Jiří
Year of publication	2021
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF) - conference abstract from 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021.
Related projects:	Český národní uzel Evropské sítě infrastruktur klinického výzkumu (CZECRIN)